Seeking Alpha

KarinCA's  Instablog

Send Message
I'm an independent trader/investor whose primary interests are in the stem cell and biotech arena. My secondary interest is in oil/energy speculation. I do venture elsewhere at times. There’s an option to follow me at the top of any article I write. Click it and you’ll also see an option to get... More
View KarinCA's Instablogs on:
  • TKMR And It's TKM-Ebola Therapy

    The next meaningful headline may come out of the meeting being held on Sept 4, 2014.

    With Aid Doctors Gone, Ebola Fight Grows Harder

    "Dr. Kieny has begun cataloging available doses of experimental drugs and vaccines in preparation for a Sept. 4 meeting on their possible use and testing in the outbreak."

    I'd hate to be short if Tekmira's TKM-ebola ends up on that list of experimental treatments to be tried. And, odds are high it will be tried since the animal studies did well.

    The TKMR pipeline includes several other things of interest. The Ebola scare has brought new eyes to this.


    "Within our TKM-PLK1 clinical trial targeting GI-NET and ACC patients, we saw an additional RECIST qualifying Partial Response (PR), defined as a greater than 30 percent reduction in target tumor lesions. This patient is continuing on therapy and has achieved a 44 percent reduction in their target tumor mass, located outside of the liver. Furthermore, scans of the target tumor lesions demonstrate signs of necrosis, indicative of anti-tumor activity.

    • We have initiated a Phase I/II clinical study of TKM-PLK1 in patients with Hepatocellular Carcinoma (NYSE:HCC).

    • We intend to file an Investigational New Drug (NYSE:IND) application, or equivalent, in the second half of 2014, in order to advance our TKM-HBV program into a Phase I clinical study, with initial data available in 2015. "

    Long or short, it's a high risk play if you aren't in for a long term investment. Trading is very volatile now.

    Disclosure: The author is long TKMR.

    Aug 20 5:09 PM | Link | 2 Comments
  • CJEU Court Agrees With ISCO And UK Court. Opens Way For EU Patents To Be Filed.

    CJEU Court Agrees with ISCO and UK Court. Finds Parthenote?s not Human Embryos. This opens the way for EU patents to be filed.

    The Advocate General delivered his opinion this morning, agreeing with the UK Court and ISCO that parthenotes, because they cannot become humans, should not be considered part of the definition of a human embryo.;jsessionid=9ea7d0f130deb01dbf66d01d4f3d8605f6d772354805.e34KaxiLc3eQc40LaxqMbN4OaNyTe0?text=&docid=155123&pageIndex=0&doclang=en&mode=lst&dir=&occ=first&part=1&cid=338666
    "V - Conclusion

    80. In the light of the foregoing, I suggest that the Court should answer the question referred by the High Court of Justice, Chancery Division (Patents Court) as follows:

    Unfertilised human ova whose division and further development have been stimulated by parthenogenesis are not included in the term 'human embryos' in Article 6(2)(c) of Directive 98/44/EC of the European Parliament and of the Council of 6 July 1998 on the legal protection of biotechnological inventions as long as they are not capable of developing into a human being and have not been genetically manipulated to acquire such a capacity."

    Disclosure: The author is long ISCO.

    Jul 17 10:29 AM | Link | Comment!
  • Newly Expanded Genetic Code

    The following is a major development I simply want to pass on to others that may not have seen it:

    Scientists Add Letters to DNA's Alphabet, Raising Hope and Fear


    DNA 2.0. By adding a new base pair, X and Y, to DNA's A-T and G-C pairs, researchers will enable organisms to build proteins from as many as 172 different amino acids.

    ...the newly expanded genetic code opens the door for synthetic biologists to create microbes capable of building their proteins out of as many as 172 different amino acids, both natural and artificial-a potential boon to drug and materials developers.

    May 08 7:17 PM | Link | 1 Comment
Full index of posts »
Latest Followers


  • $SNE expecting full year loss of $2.15 bil due to drop in value of mobile communications business... That's a turnaround.
    4 days ago
  • Update: Cellceutix's Antibiotic Brilacidin Should Move Share Price Before Kevetrin Or Prurisol $CTIX
    Sep 14, 2014
  • $PSTI - 8K filed 9.11.14 ... Item 1.02. Termination of a Material Definitive Agreement.
    Sep 12, 2014
More »

Latest Comments

Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.